GlucoTrack, Inc.

Equities

GCTK

US45824Q6061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.67 ^USD	+0.60%		-4.02%	+27.72%

Jul. 01	GlucoTrack, Inc. announced that it has received $0.1 million in funding	CI
Jun. 20	Glucotrack Announces the Appointment of Andy Balo to Board of Directors	CI

GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 15, 2024 at 05:12 pm EDT

GlucoTrack, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 2.93 million compared to USD 1.29 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.4 a year ago.

Latest news about GlucoTrack, Inc.

GlucoTrack, Inc. announced that it has received $0.1 million in funding	Jun. 30	CI
Glucotrack Announces the Appointment of Andy Balo to Board of Directors	Jun. 20	CI
Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor	Jun. 13	CI
Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor	Jun. 05	CI
Glucotrack?s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study	May. 16	CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
GlucoTrack, Inc. announced that it has received $0.5 million in funding	Apr. 21	CI
Glucotrack Expanding Glucose Monitoring Technology to Epidural Space	Apr. 16	MT
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring	Apr. 16	CI
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor	Apr. 02	CI
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors	Feb. 13	CI
GlucoTrack Says Implantable Glucose Monitor Safe With High Level of Accuracy; Shares Rise	Jan. 02	MT
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor	Jan. 02	CI
GlucoTrack, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
GlucoTrack Finance Chief Jolie Kahn Resigns, James Cardwell Named New CFO	23-10-12	MT
GlucoTrack, Inc. Announces Executive Changes	23-10-12	CI
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee	23-08-31	CI
GlucoTrack, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor	23-07-25	CI
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2023.	23-06-12	CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
GlucoTrack Completes $10 Million Share Sale	23-04-17	MT
Top Midday Decliners	23-04-13	MT
GlucoTrack Prices $10 Million Securities Offering; Shares Slump	23-04-13	MT

Chart GlucoTrack, Inc.

Duration

Period

More charts

Company Profile

GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLUCOTRACK, INC.	+27.72%	9.15M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.68%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research